????10. 默克

????? 2013年研發(fā)支出：75億美元

????? 占收入的百分比：17%

????這家制藥公司總部位于美國新澤西州，最主要的研發(fā)投資領(lǐng)域是腫瘤、傳染病、疫苗和糖尿病。今年，默克的免疫抗腫瘤藥物Keytruda獲得美國食品藥品監(jiān)督管理局批文，該藥用于治療晚期黑色素瘤，而后者是一種危險(xiǎn)的皮膚癌。該公司負(fù)責(zé)全球臨床開發(fā)的高級副總裁羅伊?貝恩斯說：“我們認(rèn)為Keytruda和免疫抗腫瘤藥物讓癌癥患者的治療方式發(fā)生了根本性變化。”他表示，默克還將把該藥的研究拓展至其他30多種癌癥。（財(cái)富中文網(wǎng)）

????譯者：Charlie

????審：李翔

????10. Merck

????? R&D spending in 2013: $7.5 billion

????? As a percentage of revenue: 17%

????The N.J.-based pharmaceutical company lists its top R&D investment priorities as oncology, infectious diseases, vaccines, and diabetes. This year Merck received approval from the FDA for an immuno-oncology drug called Keytruda that treats a dangerous form of skin cancer known as advanced melanoma. “We see Keytruda and immuno-oncology drugs as a fundamental change in how we treat cancer patients,” says Dr. Roy Baynes, senior vice president of global clinical development. Merck is also extending studies of the drug to more than 30 other tumor types, he says.